SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Akoya Biosciences, Inc. (AKYA) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+86%).
- 分析师共识目标价 $2.40 (+86% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 41/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — AKYA
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.78
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.12
每股账面价值$0.00
每股营收$1.65
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$2.40 (+86%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2019 |
$-0.40 |
$42.24M |
$-14.75M |
-34.9% |
| 2020 |
$-0.45 |
$42.44M |
$-16.71M |
-39.4% |
| 2021 |
$-1.15 |
$54.92M |
$-42.94M |
-78.2% |
| 2022 |
$-1.87 |
$74.86M |
$-70.64M |
-94.4% |
| 2023 |
$-1.43 |
$96.63M |
$-63.32M |
-65.5% |
| 2024 |
$-1.12 |
$81.67M |
$-55.37M |
-67.8% |
